title: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of a loading dose regimen of three intravenous infusions with infliximab in patients with active spondyloarthropathy.
  
  
  METHODS
  A monocentre, open-label pilot study of 21 patients with different subtypes of spondyloarthropathy was conducted. Treatment resistant patients with active disease (fulfilling inclusion criteria) received three infusions of 5 mg/kg infliximab (at weeks 0, 2, and 6). Standard clinical assessments were performed at baseline, and on days 3, 7, and 14, and from then on every two weeks. In patients who fulfilled criteria for ankylosing spondylitis, axial assessment was performed at baseline and on days 14, 42, and 84.
  
  
  RESULTS
  In all global assessments (visual analogue scale of patient global assessment, patient pain assessment, doctor global assessment), erythrocyte sedimentation rate, and C reactive protein, a highly significant decrease could be seen already at day 3 (compared with baseline), which was maintained up to day 84. In patients with peripheral disease (n=18), tender and swollen joint count significantly decreased. In patients with axial disease (n=11), functional and disease activity indices significantly improved. Moreover in eight patients with psoriatic arthritis a significant decrease of the psoriasis area and severity index was observed. The treatment was well tolerated in all patients; no significant adverse events were seen.
  
  
  CONCLUSIONS
  In this open-label pilot study of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha in patients with active spondyloarthropathy, there was a fast and significant improvement of axial and peripheral articular manifestations, without major adverse experiences.
authors.affiliation: Ghent University Hospital, Department of Rheumatology, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Van den Bosch
authors.forename: E
authors.initials: E
authors.lastname: Kruithof
authors.forename: D
authors.initials: D
authors.lastname: Baeten
authors.forename: F
authors.initials: F
authors.lastname: De Keyser
authors.forename: H
authors.initials: H
authors.lastname: Mielants
authors.forename: E M
authors.initials: EM
authors.lastname: Veys
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010865:Pilot Projects; D011239:Prednisolone / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy; D013166:Spondylitis / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D000069285:Infliximab